Eli Lilly has chosen to develop a GLP-1R small molecule drug, Orforglipron (LY3502970), which is currently in multiple Phase III clinical trials
Yes, there are risks to increasing serotonin levels too quickly, particularly the development of serotonin syndrome , a potentially life-threatening condition
Copper peptides are short chains of amino acids bound to a copper ion
Gastrointestinal reactions are especially associated with treatment initiation and dose escalation
Armstrong JS, Whiteman M, Yang H, Jones DP, Sternberg Jr P
In addition to helping break addictions to alcohol and opioids, naltrexone may help reduce reward-driven eating and the intensity of food cravings